CH627079A5 - Process for preparing a protein concentrate containing immunological factors of milk origin - Google Patents
Process for preparing a protein concentrate containing immunological factors of milk origin Download PDFInfo
- Publication number
- CH627079A5 CH627079A5 CH467977A CH467977A CH627079A5 CH 627079 A5 CH627079 A5 CH 627079A5 CH 467977 A CH467977 A CH 467977A CH 467977 A CH467977 A CH 467977A CH 627079 A5 CH627079 A5 CH 627079A5
- Authority
- CH
- Switzerland
- Prior art keywords
- milk
- whey
- casein
- bacteria
- vaccine
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims description 40
- 210000004080 milk Anatomy 0.000 title claims description 40
- 239000008267 milk Substances 0.000 title claims description 39
- 239000012141 concentrate Substances 0.000 title claims description 33
- 102000004169 proteins and genes Human genes 0.000 title claims description 22
- 108090000623 proteins and genes Proteins 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 229940088592 immunologic factor Drugs 0.000 title claims description 4
- 239000000367 immunologic factor Substances 0.000 title claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 21
- 108010046377 Whey Proteins Proteins 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 102000007544 Whey Proteins Human genes 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 15
- 239000005018 casein Substances 0.000 claims description 14
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 14
- 235000021240 caseins Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000005862 Whey Substances 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 229940072221 immunoglobulins Drugs 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 208000005577 Gastroenteritis Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000006651 lactation Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 238000011146 sterile filtration Methods 0.000 claims description 5
- 238000005345 coagulation Methods 0.000 claims description 4
- 230000015271 coagulation Effects 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 238000011026 diafiltration Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 238000011045 prefiltration Methods 0.000 claims description 2
- 229940108461 rennet Drugs 0.000 claims description 2
- 108010058314 rennet Proteins 0.000 claims description 2
- 230000001143 conditioned effect Effects 0.000 claims 1
- 238000004094 preconcentration Methods 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 37
- 241000283690 Bos taurus Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 239000012465 retentate Substances 0.000 description 14
- 241001494479 Pecora Species 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000003501 co-culture Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000012466 permeate Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000010254 subcutaneous injection Methods 0.000 description 8
- 230000037406 food intake Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000022676 rumination Effects 0.000 description 5
- 208000015212 rumination disease Diseases 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000010802 sludge Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 206010067508 Low birth weight baby Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- MHQHHBYRYFICDV-UHFFFAOYSA-M sodium;pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1CC(=O)[N-]C(=O)N1 MHQHHBYRYFICDV-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011782 vitamin Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH467977A CH627079A5 (en) | 1977-04-15 | 1977-04-15 | Process for preparing a protein concentrate containing immunological factors of milk origin |
| ZA00781607A ZA781607B (en) | 1977-04-15 | 1978-03-20 | A process for the production of a protein concentrate containing immunological factors of lactic origin |
| GB11106/78A GB1573995A (en) | 1977-04-15 | 1978-03-21 | Process for the production of a protein concentrate containing immunological factors of lactic origin |
| DK131078A DK153521C (da) | 1977-04-15 | 1978-03-22 | Fremgangsmaade til fremstilling af proteinkoncentrater indeholdende immunologiske faktorer fra maelk |
| FR7808705A FR2387039A1 (fr) | 1977-04-15 | 1978-03-24 | Procede de fabrication d'un concentre proteique contenant des facteurs immunologiques d'origine lactique |
| DE19782813984 DE2813984A1 (de) | 1977-04-15 | 1978-03-31 | Verfahren zur herstellung eines proteinkonzentrats, welches immunologische faktoren der milch enthaelt |
| MX786992U MX5007E (es) | 1977-04-15 | 1978-04-03 | Procedimiento para la preparacion de un concentrado proteinico que contiene factores inmunologicos de origen lacteo |
| AR271715A AR218482A1 (es) | 1977-04-15 | 1978-04-06 | Procedimiento para la preparacion de un concentrado proteinico que contiene factores inmunologicos de origen lacteo,contra escherigia coli |
| AU34903/78A AU519091B2 (en) | 1977-04-15 | 1978-04-10 | Protein concentrate containing immunological factors of lactic origin |
| CA300,770A CA1101333A (fr) | 1977-04-15 | 1978-04-10 | Procede de fabrication d'un concentre proteique contenant des facteurs immunologiques d'origine lactique |
| PH20991A PH14031A (en) | 1977-04-15 | 1978-04-11 | Process for the production of a protein concentrate containing immunological factors of lactic origin |
| SE7804190A SE448062B (sv) | 1977-04-15 | 1978-04-13 | Sett att framstella ett proteinkoncentrat innehallande immunologiska faktorer herrorande fran mjolk |
| JP4409378A JPS53130411A (en) | 1977-04-15 | 1978-04-14 | Production of immunoglobulin containing protein concentrate |
| IT48896/78A IT1156193B (it) | 1977-04-15 | 1978-04-14 | Procedimento di fabbricazione di un concentrato proteico contenente fattori immunoglogici di origine lattica |
| NLAANVRAGE7804015,A NL187516C (nl) | 1977-04-15 | 1978-04-14 | Werkwijze voor de bereiding van een proteine-concentraat uit melk dat immunoglobulinen bevat, en geneesmiddel tegen gastro-enteritis. |
| GR55978A GR64433B (en) | 1977-04-15 | 1978-04-14 | Method for the preparation of a proteinic concentrate which contain immunagenic fautors of lactic derivation |
| ES468808A ES468808A1 (es) | 1977-04-15 | 1978-04-14 | Procedimiento para la preparacion de un concentrado protei- nico que contiene factores inmunologicos de origen lacteo. |
| OA56468A OA05938A (fr) | 1977-04-15 | 1978-04-14 | Procédé de fabrication d'un concentré protéique contenant des facteurs immunologiques d'origine lactique. |
| PH22133A PH17782A (en) | 1977-04-15 | 1979-01-29 | A method of using a protein concentrate containing immunological factors of lactic origin |
| MY294/81A MY8100294A (en) | 1977-04-15 | 1981-12-30 | A process for the production of a protein concentrate containing immunological factors of lactic origin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH467977A CH627079A5 (en) | 1977-04-15 | 1977-04-15 | Process for preparing a protein concentrate containing immunological factors of milk origin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH627079A5 true CH627079A5 (en) | 1981-12-31 |
Family
ID=4280585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH467977A CH627079A5 (en) | 1977-04-15 | 1977-04-15 | Process for preparing a protein concentrate containing immunological factors of milk origin |
Country Status (19)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE448344B (sv) * | 1978-02-06 | 1987-02-16 | Stolle Res & Dev | Antikropp for behandling av reumatoid artrit samt sett att framstella denna |
| FR2460135A1 (fr) * | 1979-07-02 | 1981-01-23 | Liotet Serge | Composition a usage externe a base de colostrum |
| EP0064103B1 (en) * | 1981-04-28 | 1985-11-06 | The Stolle Research And Development Corporation | Method of obtaining an anti-inflammatory bovine milk |
| JP2561234B2 (ja) * | 1981-05-12 | 1996-12-04 | スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション | 抗炎症剤 |
| JPS58154513A (ja) * | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| ZA836349B (en) * | 1982-09-02 | 1985-04-24 | Unilever Plc | Production of antibodies |
| JPS6112629A (ja) * | 1984-06-28 | 1986-01-21 | Lion Corp | 口腔内組成物 |
| DE3432718C1 (de) * | 1984-09-06 | 1986-05-22 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen |
| US4816252A (en) * | 1985-04-15 | 1989-03-28 | Protein Technology, Inc. | Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins |
| US4834974A (en) * | 1986-01-13 | 1989-05-30 | Protein Technologies, Inc. | Immunologically active whey fraction and recovery process |
| GB8729031D0 (en) * | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
| IE76730B1 (en) * | 1990-07-30 | 1997-11-05 | Abbott Laboraties | Method and product for the treatment of gastric disease |
| US5258178A (en) * | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
| DE4026365A1 (de) * | 1990-08-21 | 1992-02-27 | Biotest Pharma Gmbh | Sterilfiltrierte kolostralmilch |
| JPH04169539A (ja) * | 1990-11-01 | 1992-06-17 | Imuno Japan:Kk | 消化器疾患治療・予防剤およびその製造方法 |
| US5645834A (en) * | 1992-08-28 | 1997-07-08 | Immuno-Dynamics, Inc. | Method and product for treating failure of passive transfer and improving milk production in bovine species |
| JPH09503754A (ja) * | 1993-09-20 | 1997-04-15 | アナデイス・リミテツド | 初乳から免疫グロブリンを得る方法および医薬組成物におけるそれらの使用 |
| FI97269B (fi) * | 1993-10-12 | 1996-08-15 | Viable Bioproducts Ltd | Menetelmä ravintojuoman valmistamiseksi |
| ZA949789B (en) * | 1993-12-30 | 1995-10-25 | Immunotec Res Corp Ltd | Process for making undenatured whey protein concentrate |
| US5670196A (en) * | 1995-04-12 | 1997-09-23 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
| US5707678A (en) * | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
| CA2165937A1 (en) * | 1995-05-09 | 1996-11-10 | Immunotec Research Corporation Ltd. | Process for producing an undenatured whey protein concentrate |
| AUPN642795A0 (en) * | 1995-11-08 | 1995-11-30 | Northfield Laboratories Pty Ltd | Dairy compositions and methods of preparing same |
| US5772999A (en) * | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
| JP2002501526A (ja) * | 1997-05-29 | 2002-01-15 | アグリサーチ リミティド | 乳汁における免疫グロブリンａの生成方法 |
| IE970541A1 (en) † | 1997-07-25 | 1999-01-27 | Michael Anthony Folan | Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity |
| FI110752B (fi) | 1999-05-25 | 2003-03-31 | Novatreat Oy | Menetelmä ternimaidon käsittelemiseksi |
| SE0003045D0 (sv) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| KR20040045440A (ko) | 2001-09-17 | 2004-06-01 | 일라이 릴리 앤드 캄파니 | 농약 배합물 |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| DK1629850T4 (da) | 2004-08-24 | 2013-07-01 | Nutricia Nv | Næringssammensætning indeholdende ufordøjelige oligosaccharider |
| NL1033696C2 (nl) * | 2007-04-16 | 2008-10-20 | Friesland Brands Bv | Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan. |
| US8475789B2 (en) | 2008-01-22 | 2013-07-02 | Multimerics Aps | Products and methods to prevent infections |
| ES2644983T3 (es) * | 2008-05-15 | 2017-12-01 | Biosys Health Inc. | Proceso para producir fracciones de leche ricas en inmunoglobulinas secretoras |
| DK2424890T3 (en) | 2009-04-27 | 2018-09-17 | Immuron Ltd | ANTI-LPS ENHANCED IMMUNOGLOBULIN PREPARATION FOR USE IN TREATMENT AND / OR PROPHYLAXY NONALCOHOLIC STEATOHEPATITIS |
| AU2011290478B2 (en) | 2010-08-17 | 2014-11-13 | Hadasit Medical Research Services & Development Limited | Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| US10278404B2 (en) * | 2012-09-11 | 2019-05-07 | Al-Urdonia Lemudaddat Al-Ajsam Co | Immunized camel milk-based composition for the treatment or prevention of gastrointestinal infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE546837A (enrdf_load_stackoverflow) * | ||||
| DE1022356B (de) * | 1955-04-07 | 1958-01-09 | Berry Campbell | Verfahren zur Herstellung eines spezifischen Schutzstoffes gegen ein Antigen |
| DK87610C (da) * | 1955-04-07 | 1959-07-27 | Berry Campbell | Fremgangsmåde til fremstilling af specifikke beskyttelsesstoffer mod antigene stoffer. |
| FR1599671A (enrdf_load_stackoverflow) * | 1966-06-27 | 1970-07-20 | ||
| GB1211876A (en) * | 1967-11-23 | 1970-11-11 | Twyford Lab Ltd | Improvements in and relating to prophylactic and therapeutic preparations |
| NL7011786A (enrdf_load_stackoverflow) * | 1969-09-24 | 1971-03-26 | ||
| US3930039A (en) * | 1971-07-30 | 1975-12-30 | Molkerei J A Meggle Milchindus | Method of preparing a protein concentrate from whey |
| BE788120A (fr) * | 1971-09-01 | 1973-02-28 | Coca Cola Co | Traitement des proteines du petit-lait |
| US3911108A (en) * | 1973-02-14 | 1975-10-07 | Diamond Shamrock Corp | Process of producing bovine milk products containing specific antibodies |
-
1977
- 1977-04-15 CH CH467977A patent/CH627079A5/fr not_active IP Right Cessation
-
1978
- 1978-03-20 ZA ZA00781607A patent/ZA781607B/xx unknown
- 1978-03-21 GB GB11106/78A patent/GB1573995A/en not_active Expired
- 1978-03-22 DK DK131078A patent/DK153521C/da not_active IP Right Cessation
- 1978-03-24 FR FR7808705A patent/FR2387039A1/fr active Granted
- 1978-03-31 DE DE19782813984 patent/DE2813984A1/de active Granted
- 1978-04-03 MX MX786992U patent/MX5007E/es unknown
- 1978-04-06 AR AR271715A patent/AR218482A1/es active
- 1978-04-10 AU AU34903/78A patent/AU519091B2/en not_active Expired
- 1978-04-10 CA CA300,770A patent/CA1101333A/fr not_active Expired
- 1978-04-11 PH PH20991A patent/PH14031A/en unknown
- 1978-04-13 SE SE7804190A patent/SE448062B/sv not_active IP Right Cessation
- 1978-04-14 GR GR55978A patent/GR64433B/el unknown
- 1978-04-14 ES ES468808A patent/ES468808A1/es not_active Expired
- 1978-04-14 NL NLAANVRAGE7804015,A patent/NL187516C/xx not_active IP Right Cessation
- 1978-04-14 IT IT48896/78A patent/IT1156193B/it active
- 1978-04-14 JP JP4409378A patent/JPS53130411A/ja active Granted
- 1978-04-14 OA OA56468A patent/OA05938A/xx unknown
-
1979
- 1979-01-29 PH PH22133A patent/PH17782A/en unknown
-
1981
- 1981-12-30 MY MY294/81A patent/MY8100294A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE448062B (sv) | 1987-01-19 |
| IT1156193B (it) | 1987-01-28 |
| SE7804190L (sv) | 1978-10-16 |
| DE2813984C2 (enrdf_load_stackoverflow) | 1987-11-26 |
| NL7804015A (nl) | 1978-10-17 |
| AU519091B2 (en) | 1981-11-05 |
| AR218482A1 (es) | 1980-06-13 |
| FR2387039B1 (enrdf_load_stackoverflow) | 1981-07-24 |
| OA05938A (fr) | 1981-06-30 |
| MY8100294A (en) | 1981-12-31 |
| NL187516B (nl) | 1991-06-03 |
| DK153521C (da) | 1988-12-05 |
| JPS53130411A (en) | 1978-11-14 |
| PH14031A (en) | 1980-12-12 |
| ES468808A1 (es) | 1978-12-01 |
| GR64433B (en) | 1980-03-21 |
| IT7848896A0 (it) | 1978-04-14 |
| MX5007E (es) | 1983-02-14 |
| ZA781607B (en) | 1979-03-28 |
| PH17782A (en) | 1984-12-11 |
| CA1101333A (fr) | 1981-05-19 |
| AU3490378A (en) | 1979-10-18 |
| FR2387039A1 (fr) | 1978-11-10 |
| JPS6340771B2 (enrdf_load_stackoverflow) | 1988-08-12 |
| GB1573995A (en) | 1980-09-03 |
| DK153521B (da) | 1988-07-25 |
| DK131078A (da) | 1978-10-16 |
| NL187516C (nl) | 1991-11-01 |
| DE2813984A1 (de) | 1978-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1101333A (fr) | Procede de fabrication d'un concentre proteique contenant des facteurs immunologiques d'origine lactique | |
| Korhonen et al. | Bovine milk antibodies for health | |
| CA1340183C (en) | Immunologically active whey fraction and recovery process | |
| JP5762951B2 (ja) | 分泌性免疫グロブリンの豊富な乳画分の製造方法 | |
| US4816252A (en) | Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins | |
| US4784850A (en) | Process for preparing antibodies against E. Coli K-99 antigen from bovine milk | |
| US5066491A (en) | Method of disease treatment utilizing an immunologically active whey fraction | |
| CA2013941A1 (en) | Process for preparing a therapeutic agent for rotavirus infection | |
| Kaskous et al. | Bioactive properties of minor camel milk ingredients-An overview | |
| JPH04169539A (ja) | 消化器疾患治療・予防剤およびその製造方法 | |
| EP1623717A1 (en) | Composition against infection with rotavirus and process for producing the same | |
| CN109475164A (zh) | 促进脑发育的乳清制剂 | |
| CA1337265C (en) | Oral antibody therapy for patients with lowered immune response and composition therefor | |
| US5747031A (en) | Process for isolating immunoglobulins in whey | |
| JPH02160726A (ja) | ワクチン | |
| US5198213A (en) | Method of disease treatment utilizing an immunologically whey fraction | |
| JPH11512746A (ja) | 乳漿中の免疫グロブリンの単離方法 | |
| KR100460213B1 (ko) | 항체 함유 난황분말의 제조방법, 이로부터 제조된 난황분말 및 난황분말 함유 조성물 | |
| JPH04275232A (ja) | 胃炎，胃または十二指腸潰瘍予防食品 | |
| US7547770B2 (en) | Colostral fractionation process | |
| WO2009074539A1 (en) | Prevention and treatment of otitis media using iga enriched milk | |
| RU2062109C1 (ru) | Способ получения иммунного препарата | |
| JPH10509420A (ja) | 抗炎症性因子、単離の方法、および使用 | |
| CN114073765A (zh) | 一种抑制幽门螺杆菌的组合物及其应用 | |
| WO2023056736A1 (zh) | 一种富含蜜柚纤维的低乳糖乳制品的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |